Enhancement in Dissolution Rate of Atorvastatin Trihydrate Calcium by Formulating Its Porous Tablet Using Sublimation Technique
- 27 Downloads
Proposed study was aimed to formulate and evaluate atorvastatin trihydrate calcium porous tablet.
Since atorvastatin trihydrate calcium is highly unstable drug and is immensely susceptible to hydrolysis and oxidation process, sublimation technique is taken into account for preparing porous tablet by using direct compression technique. Excipient screening and pre-formulation study was conducted to evaluate the presence of drug-excipient compatibility. Formulation was optimised using central composite design (CCD) and optimized batch was further characterised by scanning electron microscopy (SEM) for identification of surface topography. Optimized formulation was also characterised with respect to FTIR, TGA analysis, compression analysis, in vitro drug release studies and stability studies.
Hardness, friability, disintegration time and drug content of optimized porous tablets were found to be 3.46 kg/cm2, 0.92%, 7.23 s and 97.00%, respectively. Compression analysis showed optimized formulation powder is soft and plastic in nature. Tensile strength studies revealed that the tensile strength increases with increase in compression pressure. SEM studies confirmed the presence of number of pores with less than 10 μm pore size. FTIR and TGA studies confirmed that there is no change in chemical structure of drug even in porous tablet. Prepared porous tablets released 85.06 ± 15.55% of drug in 25 min whereas immediate release marketed tablets and pure drug released only 59.13 ± 4.78% and 11.36 ± 2.90% of drug in a same time. The release of proposed dosage form was substantially greater than the marketed product. Preliminary profile of stability studies did not show any significant change (p > 0.05) in the results after 90 days.
Porous tablets improved release rate which confirmed that this approach may be useful to enhance the dissolution rate of atorvastatin trihydrate calcium.
KeywordsPorous tablet Porous matrix Porous drug delivery system Fast dissolving tablet Thermogravimetric analysis Heckel compression analysis Kawakita compression analysis Atorvastatin trihydrate calcium Enhanced drug release Solubility and dissolution
The authors are thankful to Dr. Reddy Laboratories, Hyderabad, for providing atorvastatin trihydrate calcium as a gift sample. Authors gratefully acknowledge the help of Dr. Praveen Khullar, Mr. D. Saravanan and Dr. Prakash Muthudoss, Sanofi-Synthelabo (India) Pvt. Ltd., Verna, Goa, for thermogravimetric analysis of samples. Authors are thankful to Flamingo Pharmaceutical Ltd., Mumbai, for Karl Fisher Titrimetry study. Authors are also thankful to Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education and Goa College of Pharmacy for providing the infrastructural facilities to complete this work.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that there is no conflict of interest.
- 2.Ahjel SW, Lupuleasa D. Enhancement of solubility and dissolution rate of different forms of atorvastatin calcium in direct compression tablet formulas. Farmacia. 2009;57(3):290–300.Google Scholar
- 3.Rodde MS, Divase GT, Devkar TB, Tekade AR. Solubility and bioavailability enhancement of poorly aqueous soluble atorvastatin: in vitro, ex vivo, and in vivo studies. Biomed Res Int. 2014;2014(463895):11.Google Scholar
- 4.Geethalakshmi A, Divya V, Mahalingan K. Enhancement of solubility and dissolution rate of atorvastatin calcium by co-solvent evaporation. World J Pharm Pharm Sci. 2013;2(5):3790–806.Google Scholar
- 6.Sharma Y, Kumar K, Padhy SK. Formulation and evaluation of atorvastatin calcium niosomes. Int J Life Sci Scienti Res. 2016;2(4):462–5.Google Scholar
- 7.Bora D, Borude P, Bhise K. Formulation and evaluation of self microemulsifying drug delivery systems of low solubility drug for enhanced solubility and dissolution. Asian J Biomed Pharm Sci. 2012;2(15):7–14.Google Scholar
- 8.Ajmeral A, Deshpande S, Kharadi S, et al. Dissolution rate enhancement of atorvastatin, fenofibrate and ezetimibe by inclusion complex with β-cyclodextrin. Asian J Pharm Clin Res. 2012;5(4):73–6.Google Scholar
- 9.Kulkarni MC, Kolhe SV. Formulation development and evaluation of atorvastatin calcium tablets using co-processed excipients. Int J Pharm Sci Rev Res. 2016;36(1):217–22.Google Scholar
- 10.Gubbi SR, Jarag R. Formulation and characterization of atorvastatin calcium liquisolid compacts. Asian J Pharm Sci. 2010;5(2):50–60.Google Scholar
- 11.Chandiran IS, Anandakirouchenane E. Enhancement of solubility of atorvastatin calcium by nanosuspension technique. Int J Biopharm. 2014;5(3):214–7.Google Scholar
- 12.Hasson KJ. Enhancement of atorvastatin tablet dissolution using acid medium. Iraqi J Pharm Sci. 2010;19(1):82–5.Google Scholar
- 13.Maniya NH, Patel SR, Murthy ZVP. Drug delivery with porous silicon films, microparticles and nanoparticles. Rev Adv Mater Sci. 2016;44:257–72.Google Scholar
- 16.Sharma S, Sher P, Badve S, et al. Adsorption of meloxicam on porous calcium silicate: characterization and tablet formulation. AAPSPharmSciTech. 2005;6(4):E618–25.Google Scholar
- 19.Singh SS, Verma R, Kumar L. Porous oral drug delivery system—tablets. Pharm Chem J. 2018. 52(6):553–61.Google Scholar
- 20.Porosity and its influence on pharmaceutical tablet dissolution profiles, 2017. Available at: https://www.azom.com/article.aspx? ArticleID=13574. Accessed on May 28, 2018.
- 21.Quodbach J, Kleinebudde P. A critical review on tablet disintegration. Pharm Dev Technol. 2016;21(6):763–74.Google Scholar
- 24.Hasegawa M. Direct compression: microcrystalline cellulose grade 12 versus classic grade 102. Pharm Technol. 2002;26:50–60.Google Scholar
- 25.Estibeiro AL, Harmalkar D, Godinho S, et al. Lacidipine porous tablets: formulation and in vitro characterization. Lat Am J Pharm. 2018;37:1764–71.Google Scholar
- 32.Kumar L, Reddy MS, Shirodkar RK, Pai GK, Krishna VT, Verma R. Preparation and characterization of fluconazole vaginal films for the treatment of vaginal candidiasis. Indian J Pharm Sci. 2013;75(5):585–90.Google Scholar
- 33.Venugopal P, Gnanaprakash K, Kumar B, et al. Development of formulation and evaluation of ramipril porous tablet by sublimation technique. Int J Biopharm. 2014;5(4):258–64.Google Scholar
- 45.Heckel RW. Density-pressure relationship in powder compaction. Trans Metall Soc AIME. 1961;221:671–5.Google Scholar
- 46.Heckel RW. An analysis of powder compaction phenomena. Trans Metall Soc AIME. 1961;221:1001–8.Google Scholar
- 50.Indian Pharmacopoeia, 2007. Volume 2. Government of India Ministry of Health & Family Welfare Ghaziabad: The Indian Pharmacopoeia Commission pp 751–52.Google Scholar
- 51.Kumar L, Reddy MS, Verma R, et al. Selection of cryoprotective agent for freeze drying of valsartan solid lipid nanoparticles. Lat Am J Pharm. 2016;35:483–9.Google Scholar
- 52.Silverstein RM, Webster FX. Infrared Spectroscopy. Spectrometric identification of organic compounds. 6th Ed. Singapore: John Wiley & Sons (Asia) Pte. Ltd. 2005;71–143.Google Scholar
- 54.Mohylyuk V, Davtian L. Effect of diluent types and soluble diluents particle size on the dissolution profile of trimetazidine dihydrochloride and caffeine from kollidon SR matrix tablets. Int J Pharm Tech Res. 2015;8(6):147–55.Google Scholar
- 55.Khan MS, Vishakante GD, Bathool A. Preparation and evaluation of sodium alginate porous dosage form as carriers for low dosed active pharmaceutical ingredients. Turk J Pharm Sci. 2012;9(2):183–98.Google Scholar
- 56.Patil BS, Rao NGR. Formulation and evaluation of fast dissolving tablets of granisetron hydrochloride by vacuum drying technique. Applied Pharm Sci. 2011;1(4):83–8.Google Scholar
- 57.Harshitha MS, Krishnan SK, Ahmed MG. Formulation and evaluation of fast dissolving tablets of nebivolol hydrochloride. Int J Appl Pharm Biolog Res. 2016;1(2):78–86.Google Scholar
- 59.Atorvastatin Tablets, Indian Pharmacopoeia. Government of India Ministry of Health & Family Welfare. 2nd ed. The Indian Pharmacopoeia Commission: Ghaziabad; 2007. p. 751.Google Scholar
- 61.Atorvastatin calcium trihydrate. European Pharmacopoeia. 8th Edition. Council of Europe. pp. 1598–1600. Available from: https://wenku.baidu.com/view/35a9708f9ec3d5bbfd0a74f3.html?re=view. Accessed on 3rd May 2019.
- 62.Atorvastatin calcium trihydrate. PubChem. NIH US National Library of Medicine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/67019418. Accessed on 3rd May 2019.
- 64.Pathan IB, Shingare PR, Kurumkar P. Formulation design and optimization of novel mouth dissolving tablets for venlafaxine hydrochloride using sublimation technique. J Pharm Res. 2013;6:593–8.Google Scholar
- 65.Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on biopharmaceutics classification system – Guidance for Industry, U.S. Department of health and human services. Food and Drug Administration (FDA), Centre for Drug Evaluation and Research (CDER), December 2017. Available from: https://www.fda.gov/downloads/Drugs/Guidances/ucm070246.pdf. Accessed on 20th June 2018.